Edifoligide and Long-Term Outcomes After Coronary Artery Bypass Grafting: PREVENT IV 5-Year Results

BACKGROUND: Edifoligide, an E2F transcription factor decoy, does not prevent vein graft failure or adverse clinical outcomes at 1-year in patients undergoing coronary artery bypass grafting (CABG). We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placeb...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lopes, Renato D., Williams, Judson B., Mehta, Rajendra H., Reyes, Eric M., Hafley, Gail E., Allen, Keith B., Mack, Michael J., Peterson, Eric D., Harrington, Robert A., Gibson, C. Michael, Califf, Robert M., Kouchoukos, Nicholas T., Ferguson, T. Bruce, Lorenz, Todd J., Alexander, John H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3677726/
https://ncbi.nlm.nih.gov/pubmed/22980305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2012.05.019
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi